In Phase C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Members will obtain treatment till condition progression or perhaps the individuals are not able to tolerate the study drugs. Ubiquitin-similar proteins that control The soundness of critical super enhancer-mediated proteins have https://abbv-744preclinicalstudie57801.blogthisbiz.com/38497335/abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers-secrets